ICOP-Pharm: could the new paradigm bridge a gap in evidence raised by 2022 ESC guidelines on cardio-oncology?

导出 LinkOut

翻译打印收藏纠错

第一作者： Israa Fadhil,Yaseen

第一单位： Baghdad Heart Center, Medical City, Bab Al-Muadham Street, Baghdad, Iraq.

作者： Israa Fadhil,Yaseen ^[1] ; Hasan Ali,Farhan ^[2]

作者单位： Baghdad Heart Center, Medical City, Bab Al-Muadham Street, Baghdad, Iraq. ^[1] Scientific Council of Cardiology, Iraqi Board for Medical Specializations, Bab Al-Muadham Street, Baghdad, Iraq. ^[2]

关键词 Cancer therapy-related cardiovascular toxicity Cardio-oncology Cardiovascular disease Guidelines

主题词人类(Humans);肿瘤(Neoplasms);医学肿瘤学(Medical Oncology);心血管疾病(Cardiovascular Diseases)

DOI 10.1093/eurheartj/ehac701

PMID 36458874

发布时间 2023-03-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

European heart journal

2023年44卷11期

912-915页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

ICOP-Pharm: could the new paradigm bridge a gap in evidence raised by 2022 ESC guidelines on cardio-oncology?

European heart journal

相似文献

European heart journal

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

ICOP-Pharm: could the new paradigm bridge a gap in evidence raised by 2022 ESC guidelines on cardio-oncology?

European heart journal

相似文献

European heart journal

相关期刊

检索历史清除